Item 8.01. Other Events. On February 9, 2023, Bellerophon Therapeutics, Inc. issued a press release announcing the clearance from China NMPA to conduct a Phase 3 clinical trial in China for INOpulse® in fibrotic interstitial lung disease. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. . Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated February 9, 2023 104 Cover Page Interactive Data File (Formatted as Inline XBRL) 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on i(…)
The Latest Press Releases